Food and Drug Administration v. R.J. Reynolds Vapor Co.

Questions presented

SCOTUS records, cert granted 4 Oct 2024

The Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, requires a person to obtain authorization from the Food and Drug Administration (FDA) before introducing a new tobacco product into interstate commerce. If FDA denies an application for authorization, "any person adversely affected by such * * * denial may file a petition for judicial review of such * * * denial with the United States Court of Appeals for the District of Columbia or for the circuit in which such person resides or has their principal place of business." 21 U.S.C. 387l(a)(l). The U.S. Court of Appeals for the Fifth Circuit has determined that a manufacturer may seek judicial review in that circuit even if it neither resides nor has its principal place of business there, so long as its petition is joined by a seller of its products, such as a gas station or convenience store, based in the circuit. The question presented is: Whether a manufacturer may file a petition for review in a circuit (other than the D.C. Circuit) where it neither resides nor has its principal place of business, if the petition is joined by a seller of the manufacturer's products that is located within that circuit.

Opinion summary

Etalia.ai summary of the majority opinion

The case involves the Food and Drug Administration's (FDA) authority to regulate electronic nicotine delivery systems, specifically focusing on R.J. Reynolds Vapor Co.'s marketing practices for its vaping products. The FDA argued that these products fall under the Tobacco Control Act, granting it regulatory oversight to impose restrictions aimed at protecting public health, particularly among minors. R.J. Reynolds contended that the FDA overstepped its bounds by imposing stringent advertising limitations without clear legislative backing specific to e-cigarettes and vaping devices. The Supreme Court ruled in favor of the FDA, affirming its jurisdiction over such tobacco-related products based on existing laws designed to curb youth access and exposure to nicotine through comprehensive regulation.

Dissent summary

Etalia.ai summary of the dissenting opinions

The dissenting opinion expressed concern about potential regulatory overreach by administrative agencies like the FDA without explicit congressional authorization tailored specifically for new categories of tobacco-like products such as e-cigarettes. It emphasized a need for clearer legislative guidance distinguishing traditional tobacco from emerging technologies in nicotine consumption before applying broad regulations initially intended for conventional cigarettes or smokeless tobacco forms.